MONOPHARMAPharmaceuticals
Mono Pharmacre Ltd — PE Ratio & Valuation Analysis
₹11.15
-4.70%
Current P/E44.60xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E46.1x3.3% below avg
⚠️
40.4% Premium to Industry
MONOPHARMA P/E 44.60x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2024 | ₹1.58 | ₹35 | 21.9x |
| 2023 | ₹0.70 | ₹49 | 70.3x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Mono Pharmacre Ltd Valuation
Mono Pharmacre Ltd (MONOPHARMA) currently trades at 44.60x earnings. The Pharmaceuticals sector average PE is 31.77x. MONOPHARMA commands a premium, reflecting high growth expectations. Historically, MONOPHARMA has traded at an average PE of 46.1x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
10.42%
Dividend Yield
0.00%
More on Mono Pharmacre Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.